Home LiteratureArticle Details
PMID: 19812577 Published · ppublish English Biography Historical Article Journal Article

Attacking cancer at its foundation.

Nature medicine ·Vol. 15 ·No. 10 ·2009-10-00 ·Pages 1153-7

Lydon N

Abstract

暂无摘要

MeSH Terms
Academic Medical Centers/organization & administration Awards and Prizes Benzamides Clinical Trials as Topic Drug Design Drug Discovery Drug Industry/organization & administration History, 20th Century History, 21st Century Humans Imatinib Mesylate Neoplasms/genetics,therapy Piperazines/chemical synthesis,chemistry,classification,therapeutic use Protein Kinase Inhibitors/chemical synthesis,chemistry,classification,therapeutic use Pyrimidines/chemical synthesis,chemistry,classification,therapeutic use United States
Chemicals
Benzamides Piperazines Protein Kinase Inhibitors Pyrimidines Imatinib Mesylate
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Lydon Nicholas
Grant Biopharma, Jackson, Wyoming, USA. nick.lydon@me.com
References (59)
59 references, click to expand
  1. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
    Science. 2001 Aug 3;293(5531):876-80 PMID: 11423618
  2. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
    Nature. 1973 Jun 1;243(5405):290-3 PMID: 4126434
  3. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase.
    Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402 PMID: 3457562
  4. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).
    Arch Pharm (Weinheim). 1996 Jul;329(7):371-6 PMID: 8764886
  5. Regulation of protein kinases activity by quercetin in Ehrlich ascites tumor cells.
    Biochim Biophys Acta. 1982 Feb 25;714(3):415-21 PMID: 6277386
  6. Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus.
    J Cell Biochem. 1992 Jul;49(3):239-50 PMID: 1644861
  7. The proteins of oncogenes.
    Sci Am. 1984 Aug;251(2):70-9 PMID: 6206561
  8. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    N Engl J Med. 2002 Aug 15;347(7):472-80 PMID: 12181401
  9. High-throughput kinase profiling as a platform for drug discovery.
    Nat Rev Drug Discov. 2008 May;7(5):391-7 PMID: 18404149
  10. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.
    FASEB J. 1992 Nov;6(14):3275-82 PMID: 1426765
  11. An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase.
    Oncogene Res. 1990;5(3):161-73 PMID: 2157186
  12. A TRANSMISSIBLE AVIAN NEOPLASM. (SARCOMA OF THE COMMON FOWL.).
    J Exp Med. 1910 Sep 1;12(5):696-705 PMID: 19867354
  13. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
    Science. 2000 Sep 15;289(5486):1938-42 PMID: 10988075
  14. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    N Engl J Med. 2003 Mar 27;348(13):1201-14 PMID: 12660384
  15. A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nat Biotechnol. 2005 Mar;23(3):329-36 PMID: 15711537
  16. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
    Blood. 1997 Dec 15;90(12):4947-52 PMID: 9389713
  17. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    JAMA. 2003 Oct 22;290(16):2149-58 PMID: 14570950
  18. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.
    Proc Natl Acad Sci U S A. 1980 Mar;77(3):1311-5 PMID: 6246487
  19. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.
    Science. 1988 Jul 1;241(4861):42-52 PMID: 3291115
  20. Gefitinib--a novel targeted approach to treating cancer.
    Nat Rev Cancer. 2004 Dec;4(12):956-65 PMID: 15573117
  21. Rational design of inhibitors that bind to inactive kinase conformations.
    Nat Chem Biol. 2006 Jul;2(7):358-64 PMID: 16783341
  22. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor.
    Science. 1983 Jul 15;221(4607):275-7 PMID: 6304883
  23. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
    J Clin Invest. 2000 Jan;105(1):3-7 PMID: 10619854
  24. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
    J Clin Oncol. 2002 Mar 15;20(6):1692-703 PMID: 11896121
  25. Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors.
    Eur J Biochem. 1992 Jul 1;207(1):265-75 PMID: 1321046
  26. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
    Blood. 2000 Aug 1;96(3):925-32 PMID: 10910906
  27. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
    Cell. 1994 Apr 22;77(2):307-16 PMID: 8168137
  28. Oncogenic kinase signalling.
    Nature. 2001 May 17;411(6835):355-65 PMID: 11357143
  29. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
    Science. 1991 Jul 26;253(5018):407-14 PMID: 1862342
  30. Imatinib: a review of its use in the management of gastrointestinal stromal tumours.
    Drugs. 2007;67(5):805-20 PMID: 17385949
  31. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Cancer Res. 2002 Aug 15;62(16):4645-55 PMID: 12183421
  32. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
    Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 PMID: 15329413
  33. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    N Engl J Med. 2002 Aug 15;347(7):481-7 PMID: 12181402
  34. Oncogenes, growth factors, and signal transduction.
    N Engl J Med. 1989 Nov 16;321(20):1383-91 PMID: 2682241
  35. A thousand and one protein kinases.
    Cell. 1987 Sep 11;50(6):823-9 PMID: 3113737
  36. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3.
    J Antibiot (Tokyo). 1986 Jan;39(1):170-3 PMID: 3005217
  37. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Cancer Res. 1996 Jan 1;56(1):100-4 PMID: 8548747
  38. Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity.
    Anal Biochem. 1992 May 15;203(1):151-7 PMID: 1381873
  39. Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus.
    J Biol Chem. 1985 Jul 5;260(13):8070-7 PMID: 2989275
  40. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2005 Feb 24;352(8):786-92 PMID: 15728811
  41. A quantitative analysis of kinase inhibitor selectivity.
    Nat Biotechnol. 2008 Jan;26(1):127-32 PMID: 18183025
  42. Protein kinases--the major drug targets of the twenty-first century?
    Nat Rev Drug Discov. 2002 Apr;1(4):309-15 PMID: 12120282
  43. ZD6474--clinical experience to date.
    Br J Cancer. 2005 Jun;92 Suppl 1:S14-20 PMID: 15928653
  44. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters.
    J Biol Chem. 1982 Jul 10;257(13):7847-51 PMID: 7085651
  45. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Science. 2004 Jun 4;304(5676):1497-500 PMID: 15118125
  46. The conformational plasticity of protein kinases.
    Cell. 2002 May 3;109(3):275-82 PMID: 12015977
  47. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
    Nat Med. 1996 May;2(5):561-6 PMID: 8616716
  48. Selecting the right patient for tumor therapy.
    Nat Med. 2004 Jun;10(6):577-8 PMID: 15170197
  49. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  50. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.
    Nature. 1984 Feb 9-15;307(5951):521-7 PMID: 6320011
  51. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.
    Science. 1988 Nov 11;242(4880):933-5 PMID: 3263702
  52. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    PLoS Med. 2005 Mar;2(3):e73 PMID: 15737014
  53. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2004 May 20;350(21):2129-39 PMID: 15118073
  54. Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase.
    Biochem J. 1992 Nov 1;287 ( Pt 3):985-93 PMID: 1280108
  55. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
    Blood. 2002 Aug 1;100(3):1088-91 PMID: 12130532
  56. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus.
    Nature. 1983 Jul 7-13;304(5921):35-9 PMID: 6306471
  57. Treatment of hypereosinophilic syndrome with imatinib mesilate.
    Lancet. 2002 May 4;359(9317):1577-8 PMID: 12047970
  58. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    N Engl J Med. 2001 Apr 5;344(14):1031-7 PMID: 11287972
  59. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 PMID: 10991971
Article Info
Journal
Nature medicine
Abbr.
Nat Med
ISSN
1546-170X
DOI
10.1038/nm1009-1153
Email
nick.lydon@me.com
Published
2009-10-00
Pages
1153-7
Language
English
Region
United States
NLM ID
9502015
Subset
IM
External Links
PubMed source DOI: 10.1038/nm1009-1153 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2